🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Efficacy and Safety of #Obinutuzumab in Active #Lupus Nephritis NEJM nejm.org/doi/full/10.10…

Use of 18F‐fluorodeoxyglucose Positron Emission Tomography to Monitor Disease Activity in Patients With Giant Cell Arteritis on Tocilizumab - Quinn - 2025 - ACR Open Rheumatology - Wiley Online Library acrjournals.onlinelibrary.wiley.com/doi/10.1002/ac…

Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry - Rheumatology | Oxford #GCA pubmed.ncbi.nlm.nih.gov/39918980/

Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease | New England Journal of Medicine ⁦NEJM⁩ nejm.org/doi/full/10.10…

Vous êtes interne, CCA ou titulaire, intéressé par la recherche sur les vascularites, inscrivez vous à la journée annuelle du GFEV 2025 le jeudi 3 avril 2025 à Paris ⁦AJI⁩ ⁦La Revue de Médecine Interne⁩ ⁦SFNDT⁩ ⁦Vincent Cottin⁩ vascularites.org/les-journees-a…

Very happy to be part of this international collaboration 🇨🇦🇫🇷🇪🇸🇳🇿🇩🇪 defining the VITT-like Monoclonal Gammopathy of Thrombotic Significance NEJM nejm.org/doi/full/10.10…

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated #vasculitis #ANCA Nature Communications nature.com/articles/s4146…

Original Article: Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (BALANCE) nej.md/3Z5bTJD Editorial: Eight Days a Week — BALANCING Duration and Efficacy nej.md/43CWzqs #IDTwitter

🧬 IgG from patients with systemic sclerosis (#SSc) alters endothelial cell molecular signatures. ✅ Proteomic & transcriptomic changes depend on ANA serotypes. ✅ Anti-topoisomerase-I positive (ATA+) patients form distinct subgroups: 📍Strong endothelial molecular changes,

Case-control study aimed to identify optimal PJP prophylaxis schedule in patients with rheumatic diseases. Tapering GCs with 12.5 mg/day of prednisone equivalent could be a reasonable timepoint to initiate withdrawal of PJP prophylaxis A&R doi.org/10.1002/art.43…

Original Article: A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis (SELECT-GCA trial) nej.md/3XBdkia #ClinicalTrials

Congratulations to Kevin Chevalier for his work about Treatment of mixed connective tissue disease published in Journal of Autoimmunity. Glad to have participated. sciencedirect.com/science/articl…

Le GFRS a le plaisir de vous annoncer sa prochaine conférence en ligne : 📆 Jeudi 19 juin 2025 - de 13h à 14h Pr. Behrouz KASSAI-KOUPAI, HCL - Hospices Civils de Lyon 🔎 Designs innovants d'essais thérapeutiques dans les maladies rares. 📂 docs.google.com/forms/d/e/1FAI…

CD45-PET imaging gives a panoramic view of in vivo immune activity bit.ly/3RNlbFY

FIBRONEER-IPF results now online at NEJM!!! Nerandomilast slowed FVC decline at 52 weeks: −114.7 ml (18 mg BID) vs −183.5 ml (placebo) Difference: +68.8 ml (p<0.001) Benefit seen with and without background antifibrotics. #ATS2025

First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate nejm.org/doi/full/10.10…

📅 Jeudi 19 juin 2025 | 13h–14h 🧪 Webinaire : Designs innovants d’essais thérapeutiques dans les maladies rares 🎙️ Pr. Behrouz KASSAI-KOUPAI (HCL – Lyon) 🔗 Inscription gratuite : docs.google.com/forms/d/e/1FAI… #MaladiesRares #EssaisCliniques #RechercheMédicale #Méthodologie

Original Article: Nerandomilast in Patients with Progressive Pulmonary Fibrosis (FIBRONEER-ILD phase 3 trial) nej.md/436a8g4 Editorial: Progress through Persistence — Turning the Page in Pulmonary Fibrosis Clinical Trials nej.md/4ljRCIX #Pulmonology

Study demonstrates that the clinical definition of scleroderma renal crisis encompassed heterogeneity in the patterns of kidney injury. kidney.pub/JASN0720 #ASNJASN

Félicitions Yannick et toute la team !